|
KMID : 0355620140400060291
|
|
Journal of Korean Association of Oral and Maxillofacial Surgeons
2014 Volume.40 No. 6 p.291 ~ p.296
|
|
|
Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts
|
|
Kwon Taek-Kyun
Song Jae-Min
Kim In-Ryoung
Park Bong-Soo
Kim Chul-Hoon
Cheong In-Kyo
Shin Sang-Hun
|
|
|
Abstract
|
|
|
Objectives:Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of bisphophonate therapy that has been reported in recent years. Osteoclastic inactivity by bisphosphonate is the known cause of BRONJ. Bone morphogenetic protein-2 (BMP-2) plays an important role in the devel-opment of bone. Recombinant human BMP-2 (rhBMP-2) is potentially useful as an activation factor for bone repair. We hypothesized that rhBMP-2 would enhance the osteoclast-osteoblast interaction related to bone remodeling.
Materials and Methods: Human fetal osteoblast cells (hFOB 1.19) were treated with 100 μM alendronate, and 100 ng/mL rhBMP-2 was added. Cells were incubated for a further 48 hours, and cell viability was measured using an MTT assay. Expression of the three cytokines from osteoblasts, receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), and macrophage colony-stimulating factor (M-CSF), were analyzed by real-time polymerase chain reaction and enzyme-linked immunosorbent assay.
Results:Cell viability was decreased to 82.75%±1.00% by alendronate and then increased to 110.43%±1.35% after treatment with rhBMP-2 (P<0.05, respectively). OPG, RANKL, and M-CSF expression were all decreased by alendronate treatment. RANKL and M-CSF expression were increased, but OPG was not significantly afected by rhBMP-2.
Conclusion:rhBMP2 does not affect OPG gene expression in hFOB, but it may increase RANKL and M-CSF gene expression.
|
|
|
KEYWORD
|
|
|
Bone morphogenetic protein-2, Alendronate, Osteoblasts, Macrophage colony-stimulating factor, RANK ligand
|
|
|
FullTexts / Linksout information
|
|
  
|
|
|
Listed journal information
|
|
 
|
|